Glenmark inks pact with SaNOtize to produce, market anti-COVID-19 nasal spray in India, other countries
The Hindu
Available in the form of a nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs
Canadian biotech firm SaNOtize Research & Development Corp. has entered into an exclusive long term agreement with Glenmark Pharmaceuticals Ltd for the manufacturing, marketing and distribution of its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India. Glenmark will also be handling other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam. “In March 2021, SaNOtize’s clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms,” Glenmark said in a statement.More Related News